185 related articles for article (PubMed ID: 23502467)
1. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.
Li J; Chen H; Mariani A; Chen D; Klatt E; Podratz K; Drapkin R; Broaddus R; Dowdy S; Jiang SW
Int J Mol Sci; 2013 Mar; 14(3):6026-43. PubMed ID: 23502467
[TBL] [Abstract][Full Text] [Related]
2. Recombinant HE4 protein promotes proliferation of pancreatic and endometrial cancer cell lines.
Lu Q; Chen H; Senkowski C; Wang J; Wang X; Brower S; Glasgow W; Byck D; Jiang SW; Li J
Oncol Rep; 2016 Jan; 35(1):163-70. PubMed ID: 26497244
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital.
Prueksaritanond N; Cheanpracha P; Yanaranop M
Asian Pac J Cancer Prev; 2016; 17(3):1489-92. PubMed ID: 27039795
[TBL] [Abstract][Full Text] [Related]
4. Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.
Chovanec J; Selingerova I; Greplova K; Antonsen SL; Nalezinska M; Høgdall C; Høgdall E; Søgaard-Andersen E; Jochumsen KM; Fabian P; Valik D; Zdrazilova-Dubska L
Oncotarget; 2017 Dec; 8(64):108213-108222. PubMed ID: 29296235
[TBL] [Abstract][Full Text] [Related]
5. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.
Kalogera E; Scholler N; Powless C; Weaver A; Drapkin R; Li J; Jiang SW; Podratz K; Urban N; Dowdy SC
Gynecol Oncol; 2012 Feb; 124(2):270-5. PubMed ID: 22037318
[TBL] [Abstract][Full Text] [Related]
6. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.
Jiang SW; Chen H; Dowdy S; Fu A; Attewell J; Kalogera E; Drapkin R; Podratz K; Broaddus R; Li J
Int J Mol Sci; 2013 Nov; 14(11):22655-77. PubMed ID: 24252907
[TBL] [Abstract][Full Text] [Related]
7. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study.
Dewan R; Dewan A; Hare S; Bhardwaj M; Mehrotra K
J Clin Diagn Res; 2017 Jul; 11(7):XC01-XC05. PubMed ID: 28893024
[TBL] [Abstract][Full Text] [Related]
9. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.
Moore RG; Hill EK; Horan T; Yano N; Kim K; MacLaughlan S; Lambert-Messerlian G; Tseng YD; Padbury JF; Miller MC; Lange TS; Singh RK
Sci Rep; 2014 Jan; 4():3574. PubMed ID: 24389815
[TBL] [Abstract][Full Text] [Related]
10. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer and normal fallopian tube high WFDC2 expression does not correlate with HE4 serum level.
Gąsiorowska E; Walkowiak GP; Warchoł W; Lemańska A; Jankowska A; Nowak-Markwitz E
Ginekol Pol; 2015 May; 86(5):335-9. PubMed ID: 26117969
[TBL] [Abstract][Full Text] [Related]
12. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
13. HE4 as a Biomarker for Endometrial Cancer.
Behrouzi R; Barr CE; Crosbie EJ
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638250
[TBL] [Abstract][Full Text] [Related]
14. A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression.
James NE; Gura M; Woodman M; Freiman RN; Ribeiro JR
Med Oncol; 2022 May; 39(5):71. PubMed ID: 35568777
[TBL] [Abstract][Full Text] [Related]
15. Preoperative markers for the prediction of high-risk features in endometrial cancer.
Panyavaranant P; Manchana T
World J Clin Oncol; 2020 Jun; 11(6):378-388. PubMed ID: 32874951
[TBL] [Abstract][Full Text] [Related]
16. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.
Chen Y; Ren YL; Li N; Yi XF; Wang HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1974-85. PubMed ID: 27249595
[TBL] [Abstract][Full Text] [Related]
17. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
18. Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer.
Zamani N; Modares Gilani M; Zamani F; Zamani MH
J Family Reprod Health; 2015 Nov; 9(4):177-83. PubMed ID: 27047564
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
20. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
